Precision Oncology Driving Growth in CDx Market

Advancements in cancer treatment methodologies are leading to a shift towards precision oncology, emphasizing the importance of companion diagnostics (CDx) in determining patient eligibility for targeted therapies. GlobalData’s recent report indicates that the oncology diagnostics market is expected to exceed $3.1 billion by 2030, marking a significant increase from $1.9 billion in 2022. The report highlights that oncology is currently the primary area for both pipeline and marketed CDx devices. The use of CDx in oncology is vital for enhancing treatment efficacy by accurately identifying patients who will benefit from specific targeted therapies.

Russell Bradley, president of CNSide, a developer of rare cancer assays, emphasized the critical role of CDx in aligning patient-specific characteristics with the most suitable treatment approach. He noted that the evolving landscape of targeted cancer therapies necessitates precise diagnostic tools to ensure optimal therapeutic outcomes for patients. Bradley anticipates a growing synergy between targeted cancer therapies and precision diagnostics, driven by the advancement of personalized and effective treatments.

Despite the benefits of CDx in guiding treatment decisions, diagnostic test developers face challenges in implementing these tools due to the rigorous regulatory approval process. Bradley pointed out that obtaining regulatory approval for CDx can be resource-intensive and time-consuming, with disparities between the risks and rewards for diagnostic developers compared to therapeutic developers. Factors such as time to market, regulatory requirements, limited reimbursement, and the size of the diagnostic market for specific therapeutic indications can pose obstacles for diagnostic test developers.

In a significant development for the in vitro diagnostic (IVD) and CDx sector, a Texas court ruling overturned the FDA’s plans to classify IVDs, also known as laboratory-developed tests (LDTs), as medical devices in April 2025. The FDA’s ‘Final Rule,’ issued in May 2024, intended to subject IVDs to the same regulatory standards as medical devices, which was met with resistance from the diagnostics industry. Susan van Meter, president of the American Clinical Laboratory Association (ACLA), welcomed the court’s decision, emphasizing that it safeguards patient access to essential testing services and alleviates burdensome regulatory constraints on clinical laboratories in the United States.

In conclusion, the increasing adoption of precision oncology approaches underscores the growing significance of companion diagnostics in oncology. As the oncology diagnostics market continues to expand, the integration of CDx with targeted therapies has the potential to revolutionize cancer treatment strategies by delivering tailored and effective therapeutic interventions. However, addressing regulatory hurdles and aligning the interests of diagnostic and therapeutic developers are essential to leverage the full potential of CDx in improving patient outcomes in oncology.